Bridgebio Pharma, INC Form 4 insider transactions

BridgeBio Pharma Director Andrea Ellis exercised stock options and subsequently sold a portion of the acquired common stock.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, sold 2,000 shares of common stock at $66 per share under a Rule 10b5-1 sales plan.

BridgeBio Pharma CEO Neil Kumar sold 28,053 shares of common stock for approximately $2 million through a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma CEO Neil Kumar reported the conversion of Restricted Stock Units into common stock and subsequent tax-related share disposals.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported the sale of 510 common shares under a pre-arranged 10b5-1 trading plan, alongside shares withheld for tax obligations.

BridgeBio Pharma's President and CFO, Thomas Trimarchi, reported the sale of 13,600 shares and tax-related withholding of 18,819 shares of common stock.

BridgeBio Pharma Director Randal W. Scott exercised options and sold 10,000 shares of common stock on February 17, 2026, under a pre-arranged 10b5-1 plan.

BridgeBio Pharma CEO Neil Kumar executed pre-planned sales of common stock totaling 79,900 shares across two trusts on February 10 and 11, 2026, for approximately $5.7 million.

BridgeBio Pharma CEO Neil Kumar executed pre-scheduled sales of 80,000 common shares totaling approximately $6 million through a Rule 10b5-1 plan.

BridgeBio Pharma CEO Neil Kumar reported the vesting of Restricted Stock Units and subsequent sale of common stock, partially to cover tax obligations, under a pre-arranged 10b5-1 plan.

BridgeBio Pharma's President and CFO, Thomas Trimarchi, disposed of 13,826 shares of common stock to cover tax obligations related to RSU vesting.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported the disposition of 2,003 common shares to cover tax obligations related to RSU vesting.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, sold 2,000 shares of common stock for $74.26 per share under a pre-arranged 10b5-1 plan.

BridgeBio Pharma CEO Neil Kumar reported the sale of 79,000 shares of common stock through pre-arranged 10b5-1 plans in early December 2025.

BridgeBio Pharma CEO Neil Kumar sold 26,156 shares of common stock for approximately $1.7 million under a pre-arranged 10b5-1 trading plan.

BridgeBio Pharma Director Andrew Lo reported the sale of 95,599 shares of common stock across multiple transactions in mid-November 2025, executed under a Rule 10b5-1 plan.

BridgeBio Pharma Director Randal W. Scott exercised stock options and subsequently sold a portion of his shares under a Rule 10b5-1 plan.

BridgeBio Pharma CEO Neil Kumar reported the vesting of Restricted Stock Units and subsequent tax-related share withholding on November 16, 2025.

BridgeBio Pharma's President and CFO, Thomas Trimarchi, reported the sale of common stock and shares withheld for tax obligations, reducing his direct beneficial ownership.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, disposed of 4,781 shares of common stock to cover tax obligations related to RSU vesting.

BridgeBio Pharma Director Hannah Valantine exercised stock options and subsequently sold all acquired shares under a pre-arranged 10b5-1 plan.

BridgeBio Pharma CEO Neil Kumar sold 80,000 shares of common stock through two trusts as part of a pre-established Rule 10b5-1 trading plan.

BridgeBio Pharma Director Ronald J. Daniels exercised stock options and subsequently sold 61,031 shares under a pre-arranged trading plan.

BridgeBio Pharma Director Frank McCormick sold over 198,000 shares of common stock for approximately $13.3 million under a pre-arranged 10b5-1 trading plan.

BridgeBio Pharma Director Frank McCormick sold 1,641 shares of common stock for $65 per share on October 27, 2025, as part of a pre-arranged 10b5-1 plan.

BridgeBio Pharma LLC acquired 784,720 shares of BridgeBio Oncology Therapeutics, Inc. common stock, increasing its beneficial ownership to 14,589,846 shares, in exchange for additional financial and accounting support services.

BridgeBio Pharma CEO Neil Kumar sold 80,000 shares of common stock for approximately $4.38 million through pre-arranged Rule 10b5-1 plans.

BridgeBio Director Frank McCormick sells 74,000 shares for $3.9M.

BridgeBio Pharma CEO Neil Kumar sold 79,000 shares of common stock in early September 2025 through pre-arranged 10b5-1 plans.

BridgeBio Pharma's President and CFO, Thomas Trimarchi, reported the sale of 42,237 shares of common stock for approximately $2.09 million.